Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-01-15 Director's Dealing
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-01-15 English
4
Director's Dealing
2025-01-15 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the submission of matters to a vote of security holders at the company's Annual Meeting held on January 9, 2025. It includes voting results for the election of directors, ratification of the independent auditor, and approval of an equity incentive plan amendment. This corresponds to the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official shareholder vote outcomes from a general meeting. The document is about 5,481 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2025-01-13 English
FORM 4
Director's Dealing
2025-01-13 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC Division of Corporation Finance regarding an Amendment No. 2 to a Registration Statement on Form S-4 filed by Rafael Holdings, Inc. It discusses responses to SEC staff comments, updates to pro forma financial information, and revisions to risk factors referencing a Form 10-K. The document is a letter responding to regulatory comments and does not contain the actual Registration Statement or financial reports themselves. It is short (3479 characters) and serves as a regulatory filing correspondence rather than a full report or announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and regulatory communications that do not fit other categories.
2025-01-10 English
REGISTRATION STATEMENT
Merger & Acquisition Classification · 100% confidence The document is a Form S-4/A Registration Statement filed with the SEC, dated January 10, 2025. It relates to a merger transaction between Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. The text includes detailed information about the merger agreement, exchange ratio, stockholder meetings, and proxy statements. The presence of a joint proxy statement/prospectus and detailed merger terms indicates this is a filing related to merger activity. Form S-4 is specifically used for securities registration in connection with mergers and acquisitions. Therefore, this document is best classified under Merger & Acquisition filings.
2025-01-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.